Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Starpharma scores EU, UK coup

Posted 23 February 2021 PM

Starpharma's OTC Covid nasal spray Viraleze has been approved for sale in Europe, including in the UK after results showed it could rapidly inactivate more than 99.9 per cent of the virus within 60 seconds.

With the registration "ahead of schedule," according to Starpharma's CEO Jackie Fairley, the company has prepared the product to be available for sale online, direct to European and UK consumers as soon as next month.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Approvals Action
Pfizer vs Humira
Adds to a growing list of adalimumab biosims
Top of the Hill
How not to reform the PBAC
In the face of deep change, is piecemeal enough?
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas